Variant Ii Hemoglobin A1C
Assay, Glycosylated Hemoglobin. 510(k) K040872, from Bio-Rad Laboratories, Inc. (Hercules, CA). Product code LCP, class 2.
As of Nov 20, 2026, K040872 is an FDA 510(k) held by Bio-Rad Laboratories, Inc., substantially equivalent on Apr 15, 2004 after 13 days, with 4 recalls tied to it in FDA's recall database.
- Review time: 13 days
- Recalls: 4
- Cited as a predicate by: 1 device
The Bio-Rad VARIANT II TURBO Hemoglobin $A_{lc}$ Program is intended for the percent determination of hemoglobin $A_{lc}$ in human whole blood using ion-exchange high-performance liquid chromatography (HPLC). The Bio-Rad VARIANT II TURBO Hemoglobin $A_{1c}$ Program is intended for Professional Use Only. For In Vitro Diagnostic Use.
- Variant Ii Hemoglobin A1C ProgramK984268 · Bio-Rad · Dec 17, 1998
- Variant Ii Turbo Hemoglobin A1C Program, Hemoglobin Testing System With Cdm 4.0K063400 · Bio-Rad Laboratories, Inc. · Dec 1, 2006
| Sep 12, 2011 | Z-0021-2012, Z-0020-2012, Z-0022-2012A previous recall related to reports of calibration failure and late retention times using Elution Buffer led to an examination of other buffers manufactured during the same time period and a decision was made to field… | Terminated |
| Mar 24, 2010 | Z-1342-2011The firm received customer complaints associated with the Update Kit CD-ROM not being able to generate a valid calibration after being uploaded, resulting in patient results not being generated. | Terminated |
- Q-Pad Test SystemK231465 · Qurasense · Dec 6, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional, third-party review
- Received
- Apr 2, 2004
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7470
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files